Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 11/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465250 | 0.88 | PRKAG1 (0.39) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296970 | 0.84 | ALPL (0.42) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296952 | 0.82 | RXRA (0.51) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL25464969 | 0.82 | HAO1 (0.34) | PRKAG1PRKAA1PRKAB1HAO1 | |
| SCHEMBL21296847 | 0.82 | PRKAG1 (0.51) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21296854 | 0.82 | HAO1 (0.44) | PRKAG1PRKAA1PRKAB1HAO1MCL1 | |
| SCHEMBL21296913 | 0.81 | RXRA (0.45) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21312672 | 0.81 | HAO1 (0.41) | PRKAG1PRKAA1PRKAB1HAO1ALPL | |
| SCHEMBL21312442 | 0.80 | GAA (0.45) | HAO1ALPL | |
| SCHEMBL23319961 | 0.80 | HAO1 (0.39) | PRKAG1PRKAA1PRKAB1HAO1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | PRKAG1 2945/4885PRKAA1 2067/4885PRKAB1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.